Carlsmed, Inc.

Carlsmed is a publicly traded medical technology company specializing in AI-enabled personalized spine surgery solutions. The company's flagship aprevo® platform integrates artificial intelligence and 3D printing technology to design custom titanium spinal implants and deliver detailed, patient-specific surgical plans. The platform includes 3D surgical planning and visualization (myaprevo®), personalized procedural protocols, and biomechanically optimized implants designed to promote fusion. FDA-cleared for lumbar and cervical spinal fusion procedures, Carlsmed has completed over 50 cases. The company targets the substantial U.S. market opportunity of approximately 445,000 annual lumbar spine fusion procedures. With strong clinical evidence foundation and ISO 13485 certification, Carlsmed is expanding internationally following its July 2025 IPO.